Development of high-level ceftazidime resistance via single-base substitutions of blaCTX-M-3 in hyper-mutable Escherichia coli

Clinical Microbiology and Infection

Volumn 12, Issue 8, 2006, Pages 803-806

  Karisik, Edi ^a   Ellington, M J ^a   Pike, R ^a   Livermore, D M ^a   Woodford, N ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Ceftazidime; CTX M enzymes; Escherichia coli; Resistance; Selection; Lactamase

Indexed keywords

BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORINASE; CLAVULANIC ACID; KANAMYCIN; PIPERACILLIN PLUS TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; ELECTROPORATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PLATE COUNT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; WILD TYPE;

ESCHERICHIA COLI;

EID: 33745610439     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01423.x     Document Type: Article

References (14)

1. Hall BG, Barlow M. Evolution of the serine beta-lactamases: Past, present and future. Drug Resist Update 2004; 7: 111-123.
2. Bonnet R. Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
3. Sturenburg E, Kuhn A, Mack D, Laufs R. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. J Antimicrob Chemother 2004; 54: 406-409.
4. Munday CJ, Boyd DA, Brenwald N et al. Molecular and kinetic comparison of the novel extended-spectrum beta-lactamases CTX-M-25 and CTX-M-26. Antimicrob Agents Chemother 2004; 48: 4829-4834.
5. Poirel L, Naas T, Le Thomas I et al. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 2001; 45: 3355-3361.
6. Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother 2002; 50: 1031-1034.
7. Stepanova M, Shevchenko O, Edelstein M. In vivo evolution and emergence of a new CTX-M beta-lactamase with 'ceftazidimase' activity in a hypermutable clinical strain [abstract C1-60]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2005; 58.
8. Woodford N, Ward ME, Kaufmann ME et. al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-743.
9. Chopra I, O'Neill AJ, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Update 2003; 6: 137-145.
10. LeClerc JE, Li B, Payne WL, Cebula TA. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274: 1208-1211.
11. Miller K, O'Neill AJ, Chopra I. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J Antimicrob Chemother 2002; 49: 925-934.
12. Kovach ME, Elzer PH, Hill DS et al. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 1995; 166: 175-176.
13. Andrews JM. BSAC standardized disc susceptibility testing method (version 3). J Antimicrob Chemother 2004; 53: 713-728.
14. Welsh KJ, Barlow M, Tenover FC et al. Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2005; 49: 1242-1244.